利拉格卢提德调节了老鼠的形态功能和炎症性胃肠道反应
Jhony Willams Gusmão-Nascimento1, Daniela Maione Nunes Cruz2, Loyane Almeida Gama3
1Postgraduate Program in Biotechnology, Rede Nordeste de Biotecnologia (RENORBIO), Federal University of Alagoas, Maceió, Brazil.
European journal of clinical investigation
|October 17, 2023
概括
在肥胖大鼠中,利拉格卢提德治疗减少了脂肪积累,改善了代谢健康. 它还降低了肠道中的炎症标志物,这表明对与肥胖有关的炎症有潜在的益处.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 代谢研究研究 代谢研究
背景情况:
- 肥胖与能量稳定性受损和慢性轻度炎症有关.
- 类似葡萄糖类-1 (GLP-1) 的类似物,如利拉格卢提德,用于治疗肥胖症,但其抗炎作用尚未完全理解.
- 这项研究探讨了利拉格卢提德对肥胖大鼠模型中代谢和胃肠道参数的影响.
研究的目的:
- 为了研究利拉格卢提德对肥胖大鼠的代谢参数的影响.
- 评估Liraglutide对胃肠功能和炎症标志物的影响.
- 为了确定利拉格卢提德对与肥胖相关的结果的剂量依赖性影响.
主要方法:
- 肥胖的Wistar大鼠每天接受400微克/千克或1200微克/千克Liraglutide的皮下注射,持续30天.
- 测量包括体重增加,养效率,热量摄入,胃机动性,脂肪和十二指肠组织细胞因子 (TNF-α,TGF-β1).
- 统计分析涉及ANOVA或Kruskal-Wallis测试,并进行适当的后期比较.
主要成果:
- 利拉格卢提德提高了养效率和取决于剂量的热量摄入量.
- 较高的利拉格卢提德剂量减少了胃排空,肠道肌肉厚度和密室深度.
- 观察到脂肪组织,胆固醇,甘油三和肝转氨酶的显著减少. 在高剂量利拉格卢提德的使用中,TNF-α降低,而TGF-β1在十二指肠组织中增加.
结论:
- 利拉格卢提德有效地降低了肥胖大鼠的脂肪积累,并改善了代谢概况.
- 该药物调节了十二指肠组织中的炎症信号,降低了TNF-α,增加了TGF-β1.1.
- 利拉格卢提德的抗肥胖作用似乎与通过肠道GLP-1受体激活来减缓胃机动性有关.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
01:17Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
01:29Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
272
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
272
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148